James Tyree Biography and Net Worth

Director of ChemoCentryx

Mr. Tyree has served on our board of directors since June 2012. During the last fourteen years, Mr. Tyree has held numerous executive positions at Abbott Laboratories, including Corporate Vice President Pharmaceutical and Nutritional Products Group Business Development, Senior Vice President Global Nutrition and Executive Vice President Global Pharmaceuticals. He retired as President Abbott Biotechnology Ventures on March 31, 2012. Prior to joining Abbott, Mr. Tyree was the President of SUGEN, Inc., a biotechnology company focused on oncology. Earlier in his career, Mr. Tyree held management positions in Bristol-Myers Squibb, Pfizer and Abbott. Over his entire career, he was a four time expatriate living and working over six years in Latin America and seven years in Japan. Mr. Tyree is a member of the Advisory Board of the University of Chicago Graduate School of Business (BOOTH), a member of the Chicago Council on Global Affairs and co-chairman of the Global Health Policy Roundtable. Mr. Tyree also serves as a director for a number of privately held companies. Mr. Tyree earned Bachelor's Degrees in Psychology and Forensic Studies and a Master's Degree in Business Administration from Indiana University.

What is James L. Tyree's net worth?

The estimated net worth of James L. Tyree is at least $472,343.22 as of August 4th, 2022. Mr. Tyree owns 9,138 shares of ChemoCentryx stock worth more than $472,343 as of September 29th. This net worth approximation does not reflect any other investments that Mr. Tyree may own. Learn More about James L. Tyree's net worth.

How do I contact James L. Tyree?

The corporate mailing address for Mr. Tyree and other ChemoCentryx executives is 850 MAUDE AVENUE, MOUNTAIN VIEW CA, 94043. ChemoCentryx can also be reached via phone at (650) 210-2900 and via email at [email protected] Learn More on James L. Tyree's contact information.

Has James L. Tyree been buying or selling shares of ChemoCentryx?

During the last quarter, James L. Tyree has sold $502,200.00 in shares of ChemoCentryx stock. Most recently, James L. Tyree sold 10,000 shares of the business's stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $50.22, for a transaction totalling $502,200.00. Following the completion of the sale, the director now directly owns 9,138 shares of the company's stock, valued at $458,910.36. Learn More on James L. Tyree's trading history.

Who are ChemoCentryx's active insiders?

ChemoCentryx's insider roster includes Tausif Butt (COO), Thomas Edwards (Director), Geoffrey Parker (Director), Thomas Schall (CEO), and James Tyree (Director). Learn More on ChemoCentryx's active insiders.

Are insiders buying or selling shares of ChemoCentryx?

During the last year, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 4,255,123 shares worth more than $169,882,212.42. The most recent insider tranaction occured on August, 16th when CFO Susan M Kanaya sold 19,898 shares worth more than $1,013,803.10. Insiders at ChemoCentryx own 8.3 % of the company. Learn More about insider trades at ChemoCentryx.

Information on this page was last updated on 8/16/2022.

James L. Tyree Insider Trading History at ChemoCentryx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/4/2022Sell10,000$50.22$502,200.009,138View SEC Filing Icon  
6/9/2022Sell3,863$25.66$99,124.5819,138View SEC Filing Icon  
12/17/2021Sell37,500$35.02$1,313,250.00View SEC Filing Icon  
5/21/2021Sell2,454$9.76$23,951.0417,729View SEC Filing Icon  
1/13/2020Sell30,000$37.06$1,111,800.0020,060View SEC Filing Icon  
5/23/2016Sell5,544$4.39$24,338.1626,119View SEC Filing Icon  
See Full Table

James L. Tyree Buying and Selling Activity at ChemoCentryx

This chart shows James L Tyree's buying and selling at ChemoCentryx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ChemoCentryx Company Overview

ChemoCentryx logo
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $51.66
Low: $51.64
High: $51.73

50 Day Range

MA: $45.63
Low: $22.17
High: $51.80

2 Week Range

Now: $51.66
Low: $14.95
High: $51.85


48,057 shs

Average Volume

1,454,699 shs

Market Capitalization

$3.69 billion

P/E Ratio


Dividend Yield